TVTX Insider Trading

Insider Ownership Percentage: 4.06%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,178,570.17

Travere Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Travere Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Travere Therapeutics Share Price & Price History

Current Price: $14.50
Price Change: Price Increase of +1.01 (7.49%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for TVTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$14.50Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Travere Therapeutics (NASDAQ:TVTX)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TVTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$197kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More on Travere Therapeutics

Today's Range

Now: $14.50
Low: $13.14
High: $14.67

50 Day Range

MA: $19.60
Low: $13.49
High: $23.75

52 Week Range

Now: $14.50
Low: $5.12
High: $25.29

Volume

1,615,914 shs

Average Volume

1,518,274 shs

Market Capitalization

$1.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Who are the company insiders with the largest holdings of Travere Therapeutics?

Travere Therapeutics' top insider investors include:
  1. Eric M Dube (CEO)
  2. Peter Heerma (Insider)
  3. William E Rote (SVP)
  4. Christopher R Cline (CFO)
  5. Jula Inrig (Insider)
  6. Jeffrey A Meckler (Director)
  7. Sandra Calvin (CAO)
  8. Elizabeth E Reed (SVP)
  9. Gary A Lyons (Director)
  10. Roy D Baynes (Director)
Learn More about top insider investors at Travere Therapeutics.

Who are the major institutional investors of Travere Therapeutics?

Travere Therapeutics' top institutional shareholders include:
  1. Rhumbline Advisers — 0.14%
  2. GAMMA Investing LLC — 0.01%
Learn More about top institutional investors of Travere Therapeutics stock.

Which institutional investors are buying Travere Therapeutics stock?

Within the last quarter, TVTX stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. Rhumbline Advisers